Prostate International is a leading open-access journal published by Elsevier Inc, dedicated to advancing research and knowledge in the field of urology, particularly focusing on prostate health and disease. Since its inception in 2013, the journal has preserved its commitment to disseminating high-quality, peer-reviewed articles that contribute significantly to clinical practices and scientific understanding. With an impressive Q1 ranking in urology and a current position as rank #35/120 among urology journals in Scopus, it occupies a prominent place in the academic landscape, ensuring that cutting-edge research reaches a broad audience. The journal's open-access policy enhances visibility and accessibility, fostering collaboration among researchers, healthcare professionals, and students. With the range of topics covered, from innovative treatments to diagnostic advancements, Prostate International serves as a vital resource for those committed to improving patient outcomes and driving the future of urological health.

Urology Practice is a distinguished journal dedicated to advancing knowledge and practice in the field of urology. Published by Lippincott Williams & Wilkins, this journal has been pivotal in providing a platform for the dissemination of innovative research and clinical findings since its inception in 2014. With an ISSN of 2352-0779 and an E-ISSN of 2352-0787, the journal is indexed in Scopus, ranking #73 out of 120 in the Urology category, placing it in the 39th percentile. As part of the Q3 quartile in Urology for 2023, Urology Practice contributes significantly to the evolving landscape of urological medicine, offering vital insights to researchers, healthcare professionals, and students alike. While currently not an open-access journal, its valuable content remains accessible through traditional subscription-based models, catering to a global audience keen on enhancing their expertise in urology. The journal's commitment to excellence and its rigorous peer-review process ensure that published articles uphold the highest standards of scientific integrity, making it an essential resource for those engaged in urological research and clinical practice.

Canadian Journal of Urology, published by CANADIAN J UROLOGY, is a prominent peer-reviewed journal dedicated to advancing the field of urology and its allied disciplines. Established in 2000, this journal has consistently aimed to provide a platform for comprehensive research, clinical studies, and innovative practices in urology and general medicine, ensuring that professionals remain at the forefront of medical advancements. With a reputation reflected in its 2023 Scopus ranking of Q3 in both Urology and Medicine (miscellaneous), the journal serves as an essential resource for researchers and practitioners seeking to enhance their knowledge and application of urological sciences. Although it is not an Open Access journal, its impactful findings contribute significantly to the medical community in Canada and beyond, promoting evidence-based practices and contributing to better patient outcomes. As the journal converges into 2024, it continues to welcome high-quality submissions that explore critical challenges and advancements in urology.

PROSTATE CANCER AND PROSTATIC DISEASES, published by SpringerNature, is a prestigious international journal dedicated to advancing knowledge in the fields of cancer research, oncology, and urology, as evidenced by its Q1 rankings in 2023. Established in 1997, this journal has become a vital resource for researchers, clinicians, and healthcare professionals, offering impactful research and clinical insights on prostate health and disease. With its focus on innovative studies and comprehensive reviews, it addresses critical challenges in the management and treatment of prostate cancer, driving improvements in patient care globally. The journal's standing is further supported by its impressive Scopus rankings, placing it in the top tier of its categories. Readers can access high-quality, peer-reviewed articles that contribute significantly to ongoing medical practices and improve therapeutic strategies for prostate-related health issues.

European Urology Oncology is a premier academic journal dedicated to advancing the field of urological oncology through innovative research and interdisciplinary collaboration. Published by Elsevier and based in the Netherlands, this journal runs on the principles of providing high-quality, peer-reviewed content that meets the evolving needs of professionals in medicine, surgery, and oncology. With an impressive 2023 categorization in the Q1 quartiles across multiple disciplines including Medicine (Miscellaneous), Oncology, and Urology, the journal demonstrates its pivotal role in disseminating essential findings that enhance clinical practices. The E-ISSN of this journal is 2588-9311, ensuring accessibility to groundbreaking articles that influence treatment methodologies and patient outcomes. Researchers and professionals relying on the latest evidence in urology and oncology will find this journal essential for keeping abreast of cutting-edge developments and clinical insights that shape the future of healthcare.

Urology Annals, published by Wolters Kluwer Medknow Publications, is a premier open-access journal dedicated to advancing the field of urology through high-quality research and clinical insights. Established in India in 2009, this journal serves as a vital platform for communication among urologists, researchers, and medical professionals, aiming to enhance understanding and innovation in urological sciences. With an ISSN of 0974-7796 and an E-ISSN of 0974-7834, the journal offers unrestricted access to its content, fostering knowledge dissemination and collaboration across the global medical community. Currently ranked in the Q3 category within urology and holding a Scopus rank of #79/120, Urology Annals showcases significant contributions that align with its mission to publish original research, reviews, and case reports that address contemporary challenges in urology. The journal's ongoing commitment to remaining a leading resource in the field is reflected through its convergence of years from 2010 to 2024, ensuring that it stays at the forefront of the latest urological advancements.

Investigative and Clinical Urology is an esteemed open-access journal dedicated to advancing research and clinical practice in the field of urology. Published by the Korean Urological Association, this journal serves as a crucial platform for sharing innovative findings and discussions on urological science, treatments, and technologies. With an ISSN of 2466-0493 and an E-ISSN of 2466-054X, it has established its presence in the academic community since transitioning to open access in 2016. Positioned in the Q2 quartile of urology journals for 2023 and ranked 39th out of 120 in Scopus's urology category, it reflects a strong impact in the field with a 67th percentile ranking. This journal not only facilitates broad accessibility to high-quality research but also fosters collaboration and dialogue among researchers, professionals, and students interested in the latest advancements in urology. Operating from Seoul, South Korea, Investigative and Clinical Urology remains a pivotal resource for anyone seeking to enhance their understanding and practice in urological medicine.

Breast Cancer is a prestigious peer-reviewed journal published by SPRINGER JAPAN KK, specializing in the multifaceted domains of oncology and medical pharmacology. With an impressive impact factor and recognized within the Q1 category in multiple areas, including Medicine (miscellaneous), Radiology, and Nuclear Medicine and Imaging, this journal serves as a fundamental resource for cutting-edge research and clinical advancements in breast cancer treatment and care. Its indexed presence in renowned databases like Scopus further affirms its significance, ranking 56th in Radiology and 60th in Pharmacology. The journal aims to bridge the gap between clinical practice and scientific research by publishing original articles, reviews, and case studies that enhance understanding and improve patient outcomes. With converged content available from 1994 to 2024, the journal is dedicated to fostering innovative research while engaging a global audience of researchers, clinicians, and students passionate about tackling breast cancer challenges.

UROLOGY is a prestigious journal published by Elsevier Science Inc, renowned for disseminating high-quality research and reviews in the field of urology. With an ISSN of 0090-4295 and E-ISSN 1527-9995, this journal has been a trusted resource since its inception in 1973 and continues to provide insights into the latest advancements and clinical practices in urology, maintaining a category quartile of Q2 as of 2023. The journal ranks 50th out of 120 in the Scopus metrics for Medicine - Urology, placing it in the 58th percentile, which underscores its influence and relevance in the academic community. Although it is not structured as an open access journal, it offers a wealth of knowledge vital for researchers, healthcare professionals, and students alike, enabling them to stay abreast of evolving treatments and innovations in the field. As we move towards 2024, UROLOGY remains committed to advancing research and enhancing practices in urological care, fostering a collaborative environment among its readership.

BMC Urology is a premier open-access journal dedicated to advancing research in the field of urology, reproductive medicine, and miscellaneous aspects of medicine. Published by BMC since 2001 and based in the United Kingdom, this journal provides a platform for researchers, clinicians, and students to disseminate their findings and explore the latest innovations and advancements within these vital fields. With a notable impact factor and categorization in the Q2 quartile for various categories of medicine, BMC Urology stands as a reputable source, ranking 51st out of 120 in Urology and 44th out of 90 in Reproductive Medicine according to Scopus metrics. The journal fosters knowledge sharing through its open-access model, ensuring that research is accessible to all. As it converges from 2001 to 2024, BMC Urology continues to play a crucial role in shaping the landscape of urological research and providing invaluable insights into clinical practices.